Cross-topic event
World's first in vivo CRISPR Phase 3 success: single lonvo-z infusion cuts hereditary angioedema attacks 87%
Jun 13, 20262 reports
Jun 13, 2026
Sciencedesk view
World's first in vivo CRISPR Phase 3 success: single lonvo-z infusion cuts hereditary angioedema attacks 87%
Per Intellia Therapeutics on June 13, 2026, and simultaneous New England Journal of Medicine publication, the global Phase 3 HAELO trial (80 HAE patients, rando…
READ THE DAY'S DIGEST →
Sports/Healthdesk view
World's First In Vivo CRISPR Phase 3 Trial Succeeds for Hereditary Angioedema
Per ScienMag and The New England Journal of Medicine on June 13, 2026, a multinational randomized double-blind placebo-controlled Phase 3 trial led by Amsterdam…
READ THE DAY'S DIGEST →